Welcome to our dedicated page for Theravance Biopharma news (Ticker: TBPH), a resource for investors and traders seeking the latest updates and insights on Theravance Biopharma stock.
Theravance Biopharma, Inc. (NASDAQ: TBPH) is a leading biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. The company's mission is to pioneer a new generation of small-molecule drugs that better meet patient needs by maximizing efficacy while limiting systemic side effects.
Theravance Biopharma has a strong focus on inflammation and immunology and aims to deliver Medicines that Make a Difference® in people's lives. The company's research expertise has led to the development of the FDA-approved YUPELRI® (revefenacin) inhalation solution, the first once-daily, nebulized long-acting muscarinic antagonist (LAMA) for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Theravance Biopharma co-promotes YUPELRI with Viatris Inc. under a profit and loss sharing arrangement.
Another promising product in Theravance Biopharma's pipeline is ampreloxetine, a late-stage investigational norepinephrine reuptake inhibitor in development for the treatment of symptomatic neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy (MSA). This drug has the potential to be a first-in-class therapy, addressing a significant unmet medical need for MSA patients.
The company is also involved in strategic collaborations with other pharmaceutical companies to expand its reach and enhance its product pipeline. Their current projects and partnerships are aimed at furthering the development and commercialization of innovative therapies.
Financially, Theravance Biopharma has shown consistent performance, with significant growth in YUPELRI net sales and robust clinical trial activity. Recent achievements include positive results from a Phase III clinical trial of YUPELRI in China and ongoing enrollment in the Phase 3 CYPRESS study for ampreloxetine. These milestones underscore the company's commitment to delivering impactful therapies and driving shareholder value.
Theravance Biopharma continues to leverage its organ-selective drug development expertise to create value and improve patient outcomes. For more information, please visit www.theravance.com.
Theravance Biopharma reported Q1 2023 financial results and business updates. Key highlights include:
- YUPELRI net sales of $47.0 million, up 8% year-over-year
- YUPELRI retail new patient starts and total prescriptions up 61% and 29% respectively, reaching all-time highs
- CYPRESS Phase 3 study of ampreloxetine actively recruiting
- On track to complete $325 million capital return program by year-end; $215 million of share repurchases completed through 4/30/23
- Q1 2023 total revenue was $10.4 million, primarily from Viatris collaboration
- Net loss from continuing operations was $22.1 million in Q1 2023
- Cash, cash equivalents and marketable securities totaled $260.0 million as of March 31, 2023
The company expects full year 2023 R&D expense of $35-45 million and SG&A expense of $45-55 million, and anticipates generating non-GAAP profit in 2H 2023.
Theravance Biopharma (NASDAQ: TBPH) is set to announce its first quarter 2023 financial results on May 8, 2023, after market close. The announcement will be followed by a conference call at 5:00 pm ET, providing insights into the company’s business developments and performance metrics. Following the call, a replay will be accessible for 30 days until June 7, 2023. The company focuses on delivering innovative treatments, including its FDA-approved medication for COPD and a late-stage investigational drug for neurogenic orthostatic hypotension. The aim is to enhance shareholder value through its continuous development efforts.
Irenic Capital Management, a significant shareholder of Theravance Biopharma (NASDAQ: TBPH), expressed support for the recent appointment of Jim Kelly to the Board of Directors. Irenic believes Kelly will provide a key shareholder perspective that is essential for the boardroom. The firm commended Theravance for its efforts to enhance capital allocation, including expanding the capital return program and a proposal to declassify the Board. Irenic urged the Board to take further steps, such as reviewing strategic alternatives, accelerating the capital return program, and ensuring directors are elected on a one-year term. The emphasis remains on improving governance and value creation for shareholders.
FAQ
What is the current stock price of Theravance Biopharma (TBPH)?
What is the market cap of Theravance Biopharma (TBPH)?
What is Theravance Biopharma's primary focus?
What is YUPELRI?
What is ampreloxetine?
Who are Theravance Biopharma’s strategic partners?
What recent achievements has Theravance Biopharma made?
Where can I find more information about Theravance Biopharma’s products?
What is the purpose of the CYPRESS study?
How does Theravance Biopharma create shareholder value?
What is Theravance Biopharma’s mission?
How can I listen to Theravance Biopharma's conference calls?
